ArticleJournal of tissue engineering
Cardiac fibroblast-mediated ECM remodeling regulates maturation in an in vitro 3D engineered cardiac tissue.
Article in Journal of tissue engineering. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Human cardiovascular organoids: Biomedical applications and ethical challenges.American heart journal plus : cardiology research and practice · 2026Review
- Biomechanical stress unmasks a fibroblast-dependent hypercontractile-disarray phenotype in MYBPC3 truncation HCM.APL bioengineering · 2026Article
- Co-culturing hiPSC-cardiomyocytes and cardiac fibroblasts enhances engineered heart tissue structure and function.Stem cells translational medicine · 2026Article
- 3D bioprinting of microfluidic systems for cardiac regenerative medicine: from biofabrication to organ-on-a-chip.Journal of biological engineering · 2026Review
- Versatile hiPSC Models and Bioengineering Platforms for Investigation of Atrial Fibrosis and Fibrillation.Cells · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiac fibroblasts play an important role in heart homeostasis, regeneration, and disease by producing extracellular matrix (ECM) proteins and remodeling enzymes. Under normal conditions, fibroblasts exist in a quiescent state and maintain homeostasis, such as tissue structure and ECM turnover. However, if they become activated upon stimuli, such as injury, aging, or mechanical stress, which can lead to disease through excessive cell proliferation and ECM production. In addition to their role in disease progression, it remains unclear how cardiac fibroblasts contribute to cardiac maturation during development and whether the mechanism driving cytokine and ECM production during development aligns with those observed in pathological conditions. In this study, we investigated the functional and structural maturation of engineered cardiac tissue by modulating fibroblast activity within a three-dimensional (3D) in vitro model. In this model, human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) and human primary cardiac fibroblasts (FBs) were co-cultured in a fibrin gel and their morphology, beating characteristics, beating force, and mRNA expression profiles were analyzed. The results demonstrate that functional and structural maturation were enhanced by fibroblast-driven tissue contraction and collagen deposition, while inhibition of ECM remodeling impaired both processes. However, excessive collagen accumulation reduced functional maturation by limiting contractile efficiency. Our data suggest that ECM remodeling by cardiac fibroblasts is essential for cardiac tissue maintenance and maturation. Additionally, the regulation of collagen deposition by fibroblast activity will be a key focus of future research, as it may critically influence both cardiac development and the progression of heart disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.